Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Neurocrine Biosciences, Inc.
NBIX
$137.00
Name : Neurocrine Biosciences, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $13,587,867,648.00
EPSttm : 3.38
finviz dynamic chart for NBIX
Neurocrine Biosciences, Inc.
$137.00
1.74%
$2.43

Float Short %

4.27

Margin Of Safety %

6

Put/Call OI Ratio

1.29

EPS Next Q Diff

1.31

EPS Last/This Y

3.36

EPS This/Next Y

2.18

Price

137.03

Target Price

168.95

Analyst Recom

1.32

Performance Q

2.61

Relative Volume

0.95

Beta

0.22

Ticker: NBIX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08NBIX143.650.900.867566
2025-09-09NBIX144.180.900.357595
2025-09-10NBIX141.270.901.507605
2025-09-11NBIX143.610.900.337612
2025-09-12NBIX141.870.910.007574
2025-09-15NBIX140.450.910.017589
2025-09-16NBIX140.960.820.058014
2025-09-17NBIX142.730.749123891981030.00578034682080928485
2025-09-18NBIX145.640.770.038372
2025-09-22NBIX146.581.040.386145
2025-09-23NBIX146.451.030.006263
2025-09-24NBIX146.731.030.226264
2025-09-25NBIX141.251.0392.736273
2025-09-26NBIX142.041.3636.507291
2025-09-29NBIX140.371.282.337052
2025-09-30NBIX140.321.280.047058
2025-10-01NBIX137.041.302.066995
2025-10-02NBIX136.731.302.857022
2025-10-03NBIX136.941.434.807285
2025-10-06NBIX139.381.281.837072
2025-10-07NBIX137.021.291.037145
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08NBIX143.8015.6272.26.74
2025-09-09NBIX144.1615.6276.06.74
2025-09-10NBIX141.2915.6257.26.74
2025-09-11NBIX143.6015.6287.86.74
2025-09-12NBIX141.8215.6263.66.74
2025-09-15NBIX140.5115.6265.86.74
2025-09-16NBIX140.9015.6276.76.74
2025-09-17NBIX142.8115.6285.26.74
2025-09-18NBIX145.7115.6291.46.74
2025-09-19NBIX145.1615.6270.86.74
2025-09-22NBIX146.6215.6281.56.74
2025-09-23NBIX146.4315.6272.86.74
2025-09-24NBIX146.6315.6275.26.74
2025-09-25NBIX140.8915.6241.06.76
2025-09-26NBIX142.0015.6280.56.76
2025-09-29NBIX140.3515.6264.26.76
2025-09-30NBIX140.3315.6274.36.76
2025-10-01NBIX137.0315.6254.66.76
2025-10-02NBIX136.7515.6272.36.76
2025-10-03NBIX137.0215.6275.66.76
2025-10-06NBIX139.4315.6290.36.76
2025-10-07NBIX137.0315.6259.56.76
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08NBIX-7.773.474.13
2025-09-09NBIX-7.773.474.13
2025-09-10NBIX-7.773.474.13
2025-09-11NBIX-7.773.474.28
2025-09-12NBIX-7.773.474.28
2025-09-15NBIX-7.773.494.28
2025-09-16NBIX-7.773.494.28
2025-09-17NBIX-7.773.494.28
2025-09-18NBIX-7.773.494.28
2025-09-19NBIX-7.773.494.28
2025-09-22NBIX-7.773.494.28
2025-09-23NBIX-7.773.494.28
2025-09-24NBIX-7.773.494.28
2025-09-25NBIX-7.773.494.27
2025-09-26NBIX-7.773.494.27
2025-09-29NBIX-7.773.364.27
2025-09-30NBIX-7.773.364.27
2025-10-01NBIX-7.773.364.27
2025-10-02NBIX-7.773.364.27
2025-10-03NBIX-7.773.364.27
2025-10-06NBIX-7.773.334.27
2025-10-07NBIX-7.773.334.27
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

1.06

Avg. EPS Est. Current Quarter

2.09

Avg. EPS Est. Next Quarter

2.37

Insider Transactions

-7.77

Institutional Transactions

3.33

Beta

0.22

Average Sales Estimate Current Quarter

746

Average Sales Estimate Next Quarter

785

Fair Value

145.68

Quality Score

77

Growth Score

99

Sentiment Score

49

Actual DrawDown %

13.3

Max Drawdown 5-Year %

-42.9

Target Price

168.95

P/E

40.44

Forward P/E

21.12

PEG

1.12

P/S

5.41

P/B

5.03

P/Free Cash Flow

25.7

EPS

3.39

Average EPS Est. Cur. Y​

6.76

EPS Next Y. (Est.)

8.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.88

Relative Volume

0.95

Return on Equity vs Sector %

-12.3

Return on Equity vs Industry %

5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

259.5
Neurocrine Biosciences, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
stock quote shares NBIX – Neurocrine Biosciences, Inc. Stock Price stock today
news today NBIX – Neurocrine Biosciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NBIX – Neurocrine Biosciences, Inc. yahoo finance google finance
stock history NBIX – Neurocrine Biosciences, Inc. invest stock market
stock prices NBIX premarket after hours
ticker NBIX fair value insiders trading